[go: up one dir, main page]

MX2009008243A - Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1. - Google Patents

Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1.

Info

Publication number
MX2009008243A
MX2009008243A MX2009008243A MX2009008243A MX2009008243A MX 2009008243 A MX2009008243 A MX 2009008243A MX 2009008243 A MX2009008243 A MX 2009008243A MX 2009008243 A MX2009008243 A MX 2009008243A MX 2009008243 A MX2009008243 A MX 2009008243A
Authority
MX
Mexico
Prior art keywords
methods
release
glp
insulin
trpm5 inhibitor
Prior art date
Application number
MX2009008243A
Other languages
English (en)
Inventor
S Paul Lee
M N Tulu Buber
Rok Cerne
Peihong Zhou
Robert Bryant
F Raymond Salemme
Gillian Morgan
Original Assignee
Redpoint Bio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redpoint Bio Corp filed Critical Redpoint Bio Corp
Publication of MX2009008243A publication Critical patent/MX2009008243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para intensificar la liberación de insulina, liberación de GLP-1, y sensibilidad de insulina, métodos para incrementar la expresión del gen de insulina, métodos para reducir la secreción y vacío gástrico y secreción de glucagonas, y métodos para inhibir la absorción de alimento, y métodos para tratar diabetes mellitus, síndrome de resistencia a la insulina, hiperglicemia y obesidad, que comprende administrar a un sujeto, una cantidad efectiva de un inhibidor de TRPM5.
MX2009008243A 2007-02-02 2008-02-04 Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1. MX2009008243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88799607P 2007-02-02 2007-02-02
US1639407P 2007-12-21 2007-12-21
PCT/US2008/001445 WO2008097504A2 (en) 2007-02-02 2008-02-04 Use of a trpm5 inhibitor to regulate insulin and glp-1 release

Publications (1)

Publication Number Publication Date
MX2009008243A true MX2009008243A (es) 2009-08-12

Family

ID=39682300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008243A MX2009008243A (es) 2007-02-02 2008-02-04 Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1.

Country Status (9)

Country Link
US (1) US8193168B2 (es)
EP (1) EP2107908A4 (es)
JP (1) JP2010518008A (es)
AU (1) AU2008214338A1 (es)
BR (1) BRPI0808157A2 (es)
CA (1) CA2677230A1 (es)
MX (1) MX2009008243A (es)
RU (1) RU2009131697A (es)
WO (1) WO2008097504A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175848A1 (en) * 2007-09-17 2009-07-09 Lee S Paul Modulation of the Cooperativity Between the Ion Channels TRPM5 and TRPA1
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
KR101334466B1 (ko) 2011-02-09 2013-11-29 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
EP2505201A1 (en) * 2011-03-29 2012-10-03 Nestec S.A. Trmp5 inhibitors support body weight reduction without reducing food intake
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
LT2744330T (lt) 2011-08-15 2020-10-26 University Of Utah Research Foundation Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN110139672A (zh) 2016-12-26 2019-08-16 花王株式会社 运动调节功能提高剂
WO2020068425A1 (en) * 2018-09-26 2020-04-02 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for enhancing insulin secretion
WO2024156007A1 (en) * 2023-01-20 2024-07-25 The Research Foundation For The State University Of New York Hydrazonyl sultones and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746703A (en) * 1971-07-01 1973-07-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US5130324A (en) 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
FR2615188B1 (fr) 1987-05-14 1989-11-17 Meram Laboratoires Sa Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE3903990A1 (de) * 1989-02-10 1990-08-30 Basf Ag Phenylhydrazone, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
JPH0725761A (ja) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) * 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
AU2610299A (en) * 1998-02-05 1999-08-23 Novo Nordisk A/S Hydrazone derivatives
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6403142B1 (en) * 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
AU2378600A (en) * 1998-12-23 2000-07-31 Mount Sinai School Of Medicine Of The City University Of New York, The Inhibitors of the bitter taste response
US6773716B2 (en) * 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
AU8032400A (en) 1999-10-27 2001-05-08 Zapata Technologies, Inc. Flavor protectant closure liner compositions
AU2001241042A1 (en) 2000-03-08 2001-09-17 Takeda Chemical Industries Ltd. Process for the preparation of hydrazine derivatives
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6485709B2 (en) * 2001-01-23 2002-11-26 Addent Inc. Dental bleaching gel composition, activator system and method for activating a dental bleaching gel
EP1412327A2 (en) * 2001-05-30 2004-04-28 LG Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
JPWO2003026661A1 (ja) * 2001-09-14 2005-01-06 山之内製薬株式会社 インスリン分泌促進剤及び新規なピリミジン誘導体
JP2005513046A (ja) 2001-12-10 2005-05-12 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シクロオキシゲナーゼ−２阻害剤としての置換ヒドラゾン
KR20030095731A (ko) * 2002-06-14 2003-12-24 크리스탈지노믹스(주) 2-클로로-5-(5-하이드라조노메틸-푸란-2-일)-벤조산유도체를 포함하는 단백질 티로신 포스파타제 1ｂ 활성억제용 약학 조성물
CA2499880A1 (en) 2002-09-27 2004-04-08 University Of North Carolina At Chapel Hill Methods and compositions for modification of splicing of pre-mrna
AU2003288925A1 (en) * 2002-10-08 2004-05-04 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
EP1594922A1 (en) 2003-02-17 2005-11-16 Ciba SC Holding AG Cationic substituted hydrazone dyes
CA2516651C (en) * 2003-02-21 2013-05-07 The Queen's Medical Center Methods of screening for trpm5 modulators
CA2517981A1 (en) * 2003-03-05 2004-09-16 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
BRPI0408436A (pt) 2003-03-18 2006-04-04 Ciba Sc Holding Ag corantes diméricos catiÈnicos
WO2004087641A1 (ja) * 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. ヒドラゾン誘導体
JP2006528955A (ja) 2003-05-27 2006-12-28 ビーエーエスエフ　アクチェンゲゼルシャフト 有害な昆虫およびクモ形類を駆除するためのヒドラゾン誘導体
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
WO2005049084A2 (en) * 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
CA2608243A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Acyl hydrazones for treating cardiovascular diseases
US20070161052A1 (en) * 2005-10-19 2007-07-12 Senomyx, Inc. TRPM5 based assays and the use thereof for the identification of modulators of sweet, bitter or umami (savory) taste
CN101541348A (zh) * 2005-11-03 2009-09-23 红点生物公司 腙衍生物及其用途
BRPI0618247A2 (pt) * 2005-11-03 2011-08-23 Redpoint Bio Corp ensaio de triagem de alto rendimento para canal iÈnico trpm5
US20090324580A1 (en) 2006-03-09 2009-12-31 Cenix Bioscience Gmbh Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
EP2015638A4 (en) * 2006-04-28 2010-09-29 Redpoint Bio Corp TRIARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS TASTE INHIBITORS

Also Published As

Publication number Publication date
JP2010518008A (ja) 2010-05-27
WO2008097504A3 (en) 2008-11-20
US8193168B2 (en) 2012-06-05
US20080306030A1 (en) 2008-12-11
EP2107908A4 (en) 2011-07-20
AU2008214338A1 (en) 2008-08-14
RU2009131697A (ru) 2011-03-10
CA2677230A1 (en) 2008-08-14
BRPI0808157A2 (pt) 2014-07-01
WO2008097504A2 (en) 2008-08-14
EP2107908A2 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
MX2009008243A (es) Uso de un inhibidor de trpm5 para regular la insulina y la liberacion de glp-1.
HRP20180667T1 (hr) Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin
WO2010016944A3 (en) Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
HK1213483A1 (zh) Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
WO2010016940A3 (en) Analogues of glucose-dependent insulinotropic polypeptide
WO2010016938A3 (en) Glucose-dependent insulinotropic polypeptide analogues
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
BRPI0919946A2 (pt) tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
EP2120959A4 (en) METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
EA200870365A1 (ru) Эндотелин и агонисты рецепторов к эндотелину в лечении заболеваний обмена веществ
MY168749A (en) Exendin-4 derivatives as dual glp1/glucagon agonists
WO2010016935A3 (en) Truncated analogues of glucose-dependent insulinotropic polypeptide
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
HRP20121029T1 (hr) Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
WO2011092473A8 (en) Novel compounds and their effects on feeding behaviour
WO2013059336A8 (en) Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
PH12013502385A1 (en) Amylin peptide and derivatives and uses thereof
AU2010353685A8 (en) Novel glucagon like peptide analogs, composition, and method of use
ZA201007061B (en) Pyridopyrazinones derivatives insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
ZA201008505B (en) Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
WO2008115390A3 (en) Methods of using defensins to treat diabetes
MX2010006173A (es) Octahidroquinolizinas para tratamiento antidiabetico.
WO2009110983A8 (en) Retinaldehyde in the treatment of obesity, diabetes and other conditions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal